MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2012-10-19
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of Akt inhibitor MK2206 (MK2206)
when given together with paclitaxel and to see how well they work in treating patients with
solid tumors that have spread to other places in the body and usually cannot be cured or
controlled with treatment or breast cancer that has spread to other places in the body. Akt
inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to
stop the growth of tumor cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. Giving Akt inhibitor MK2206 and paclitaxel may be a
better treatment for solid tumors or breast cancer.